Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Donald E. Cutlip, M.D.

Title
Institution
Department
Address
Phone

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. U01HL081656 (CUTLIP, DONALD) Aug 15, 2005 - Jul 31, 2013
    NIH
    Claudication Exercise vs Endoluminal Revascularization
    Role: Principal Investigator
  2. U01HL072737 (CUTLIP, DONALD) Apr 15, 2004 - Jul 31, 2015
    NIH
    CORAL: Data Coordinating Center
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Kereiakes DJ, Feldman RL, Ijsselmuiden AJJ, Saito S, Amoroso G, Zidar JP, Wong SC, Stella P, Yakubov S, Lasala J, Cohen DJ, Doros G, Cutlip DE, Rao SV. Safety and Effectiveness of the SVELTE Fixed-Wire and Rapid Exchange Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions: Results of the OPTIMIZE Randomized Study. Circ Cardiovasc Interv. 2021 09; 14(9):e010609. PMID: 34353122.
    Citations:    Fields:    
  2. Berg DD, Yeh RW, Mauri L, Morrow DA, Kereiakes DJ, Cutlip DE, Gao Q, Jarolim P, Michelson AD, Frelinger AL, Cange AL, Sabatine MS, O'Donoghue ML. Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. J Thromb Thrombolysis. 2021 Apr; 51(3):675-681. PMID: 32683645.
    Citations: 2     Fields:    
  3. Cutlip DE. Standing the Test of Time: A Device and Patient Perspective. J Am Coll Cardiol. 2021 03 09; 77(9):1179-1181. PMID: 33663734.
    Citations:    Fields:    Translation:Humans
  4. Ybarra LF, Rinfret S, Brilakis ES, Karmpaliotis D, Azzalini L, Grantham JA, Kandzari DE, Mashayekhi K, Spratt JC, Wijeysundera HC, Ali ZA, Buller CE, Carlino M, Cohen DJ, Cutlip DE, De Martini T, Di Mario C, Farb A, Finn AV, Galassi AR, Gibson CM, Hanratty C, Hill JM, Jaffer FA, Krucoff MW, Lombardi WL, Maehara A, Magee PFA, Mehran R, Moses JW, Nicholson WJ, Onuma Y, Sianos G, Sumitsuji S, Tsuchikane E, Virmani R, Walsh SJ, Werner GS, Yamane M, Stone GW, Rinfret S, Stone GW. Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. Circulation. 2021 Feb 02; 143(5):479-500. PMID: 33523728.
    Citations: 4     Fields:    
  5. Colleran R, Joner M, Cutlip D, Urban P, Maeng M, Jauhar R, Barakat M, Michel JM, Mehran R, Kirtane AJ, Maillard L, Kastrati A, Byrne RA. Design and rationale of a randomized trial of COBRA PzF stenting to REDUCE duration of triple therapy (COBRA-REDUCE). Cardiovasc Revasc Med. 2021 Jan 22. PMID: 33608239.
    Citations: 1     Fields:    
  6. Katritsis DG, Pantos I, Zografos T, Spahillari A, de Waha A, Kopanidis A, Foussas S, Stone PH, Kastrati A, Cutlip D. Anatomic and Flow Characteristics of Left Anterior Descending Coronary Artery Angiographic Stenoses Predisposing to Myocardial Infarction. Am J Cardiol. 2021 02 15; 141:7-15. PMID: 33220322.
    Citations:    Fields:    Translation:Humans
  7. Cutlip DE. Procedural Myocardial Infarction: Definitions Everywhere, But Not Any That May Fit. J Am Coll Cardiol. 2020 10 06; 76(14):1640-1643. PMID: 33004128.
    Citations: 4     Fields:    Translation:Humans
  8. Capodanno D, Morice MC, Angiolillo DJ, Bhatt DL, Byrne RA, Colleran R, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock SJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhovel U, Krucoff MW, Urban P, Mehran R. Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel. J Am Coll Cardiol. 2020 09 22; 76(12):1468-1483. PMID: 32943165.
    Citations: 3     Fields:    Translation:Humans
  9. Marquis-Gravel G, Moliterno DJ, Francis DP, Jüni P, Rosenberg YD, Claessen BE, Mentz RJ, Mehran R, Cutlip DE, Chauhan C, Quella S, Zannad F, Goodman SG. Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 07 28; 76(4):435-450. PMID: 32703515.
    Citations: 1     Fields:    Translation:Humans
  10. Kandzari DE, Koolen JJ, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial. JACC Cardiovasc Interv. 2020 06 08; 13(11):1343-1353. PMID: 32499026.
    Citations: 6     Fields:    Translation:Humans
  11. Cutlip DE. On the Bleeding Edge: Device- or Drug-Based Solutions. Circ Cardiovasc Interv. 2020 04; 13(4):e009128. PMID: 32279569.
    Citations:    Fields:    Translation:Humans
  12. Cutlip DE. Editorial: A REMEDEE for Very Late Stent Failure? Cardiovasc Revasc Med. 2020 05; 21(5):571-572. PMID: 32061486.
    Citations:    Fields:    Translation:Humans
  13. Spitzer E, McFadden E, Rademaker-Havinga T, Cutlip DE, Garcia-Garcia HM. Reply: Periprocedural PCI Myocardial Biomarker Elevation and Mortality. JACC Cardiovasc Interv. 2020 01 27; 13(2):266-268. PMID: 31973800.
    Citations:    Fields:    Translation:Humans
  14. Chang CC, Kogame N, Onuma Y, Byrne RA, Capodanno D, Windecker S, Morel MA, Cutlip DE, Krucoff MW, Stone GW, Lansky AJ, Mehran R, Spitzer E, Fraser AG, Baumbach A, Serruys PW. Defining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology. EuroIntervention. 2020 Jan 17; 15(13):1190-1198. PMID: 31475907.
    Citations:    Fields:    Translation:Humans
  15. Cutlip DE, Urban P. Validation of Standardization: Testing the Academic Research Consortium High Bleeding Risk Criteria. Circ Cardiovasc Interv. 2019 11; 12(11):e008569. PMID: 31707806.
    Citations:    Fields:    Translation:Humans
  16. Cutlip DE. Diabetes, Kidney Disease, and Coronary Stents - A Complex Interaction. Cardiovasc Revasc Med. 2019 12; 20(12):1081-1082. PMID: 31870525.
    Citations:    Fields:    Translation:Humans
  17. Garcia-Garcia HM, McFadden EP, von Birgelen C, Rademaker-Havinga T, Spitzer E, Kleiman NS, Cohen DJ, Kennedy KF, Camenzind E, Mauri L, Steg PG, Wijns W, Silber S, van Es GA, Serruys PW, Windecker S, Cutlip D, Vranckx P. Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2019 10 14; 12(19):1954-1962. PMID: 31601389.
    Citations: 8     Fields:    Translation:HumansCells
  18. Stefanescu Schmidt AC, Steg PG, Yeh RW, Kereiakes DJ, Tanguay JF, Hsieh WH, Massaro JM, Mauri L, Cutlip DE. Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual Antiplatelet Therapy Study). Am J Cardiol. 2019 12 15; 124(12):1813-1820. PMID: 31653353.
    Citations: 2     Fields:    Translation:Humans
  19. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019 08 14; 40(31):2632-2653. PMID: 31116395.
    Citations: 29     Fields:    Translation:Humans
  20. Cooper EL, Xie Y, Nguyen H, Brewster PS, Sholl H, Sharrett M, Ren K, Chen T, Tuttle KR, Haller ST, Jamerson K, Murphy TP, D'Agostino RB, Massaro JM, Henrich W, Cooper CJ, Cutlip DE, Dworkin LD, Shapiro JI. Early Rapid Decline in Kidney Function in Medically Managed Patients With Atherosclerotic Renal Artery Stenosis. J Am Heart Assoc. 2019 06 04; 8(11):e012366. PMID: 31433717.
    Citations: 3     Fields:    Translation:Humans
  21. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation. 2019 07 16; 140(3):240-261. PMID: 31116032.
    Citations: 47     Fields:    Translation:Humans
  22. Spitzer E, McFadden E, Vranckx P, Garcia-Garcia HM, Seltzer JH, Held C, de Vries T, Menon V, Brown KJ, Soliman OII, Onuma Y, Lopes RD, Stone GW, Cutlip DE, Serruys PW. Critical Appraisal of Contemporary Clinical Endpoint Definitions in Coronary Intervention Trials: A Guidance Document. JACC Cardiovasc Interv. 2019 05 13; 12(9):805-819. PMID: 31072504.
    Citations: 1     Fields:    Translation:Humans
  23. Chen T, Brewster P, Tuttle KR, Dworkin LD, Henrich W, Greco BA, Steffes M, Tobe S, Jamerson K, Pencina K, Massaro JM, D'Agostino RB, Cutlip DE, Murphy TP, Cooper CJ, Shapiro JI. Prediction of cardiovascular outcomes with machine learning techniques: application to the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) study. Int J Nephrol Renovasc Dis. 2019; 12:49-58. PMID: 30962703.
    Citations: 2     
  24. Jones MR, Howard G, Roubin GS, Blackshear JL, Cohen DJ, Cutlip DE, Leimgruber PP, Rhodes D, Prineas RJ, Glasser SP, Lal BK, Voeks JH, Brott TG. Periprocedural Stroke and Myocardial Infarction as Risks for Long-Term Mortality in CREST. Circ Cardiovasc Qual Outcomes. 2018 11; 11(11):e004663. PMID: 30571337.
    Citations: 2     Fields:    Translation:Humans
  25. Roguin A, Kandzari DE, Marcusohn E, Koolen JJ, Doros G, Massaro JM, Garcia-Garcia HM, Bennett J, Gharib EG, Cutlip DE, Waksman R. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients. Circ Cardiovasc Interv. 2018 10; 11(10):e007331. PMID: 30354631.
    Citations: 5     Fields:    Translation:Humans
  26. Kandzari DE, Koolen JJ, Doros G, Massaro JJ, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents. J Am Coll Cardiol. 2018 12 25; 72(25):3287-3297. PMID: 30257191.
    Citations: 9     Fields:    Translation:Humans
  27. Berry NC, Kereiakes DJ, Yeh RW, Steg PG, Cutlip DE, Jacobs AK, Abbott JD, Hsieh WH, Massaro JM, Mauri L. Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women. Circ Cardiovasc Interv. 2018 08; 11(8):e005308. PMID: 30354781.
    Citations:    Fields:    Translation:Humans
  28. Cutlip DE, Fischman DL. Mortality After Percutaneous Coronary Intervention: Narrowing the Knowledge Gap. Circ Cardiovasc Interv. 2018 07; 11(7):e007008. PMID: 30006335.
    Citations: 1     Fields:    Translation:Humans
  29. Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW, Vranckx P, Windecker S, Cutlip D, Serruys PW. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Eur Heart J. 2018 06 14; 39(23):2192-2207. PMID: 29897428.
    Citations: 16     Fields:    Translation:Humans
  30. Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW, Vranckx P, Windecker S, Cutlip D, Serruys PW. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation. 2018 06 12; 137(24):2635-2650. PMID: 29891620.
    Citations: 40     Fields:    Translation:Humans
  31. Spitzer E, McFadden E, Vranckx P, de Vries T, Ren B, Collet C, Onuma Y, Garcia-Garcia HM, Lopes RD, Stone GW, Cutlip DE, Serruys PW. Defining Staged Procedures for Percutaneous Coronary Intervention Trials: A Guidance Document. JACC Cardiovasc Interv. 2018 05 14; 11(9):823-832. PMID: 29747912.
    Citations: 1     Fields:    Translation:Humans
  32. Lansky AJ, Messé SR, Brickman AM, Dwyer M, Bart van der Worp H, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, Browndyke J, Prendergast B, Ng VG, Cutlip DE, Kapadia S, Krucoff MW, Linke A, Scala Moy C, Schofer J, van Es GA, Virmani R, Popma J, Parides MK, Kodali S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, Holmes D, Kappetein AP, Mack M, Baumbach A. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. Eur Heart J. 2018 05 14; 39(19):1687-1697. PMID: 28171522.
    Citations: 1     Fields:    Translation:Humans
  33. Ruiz CE, Hahn RT, Berrebi A, Borer JS, Cutlip DE, Fontana G, Gerosa G, Ibrahim R, Jelnin V, Jilaihawi H, Jolicoeur EM, Kliger C, Kronzon I, Leipsic J, Maisano F, Millan X, Nataf P, O'Gara PT, Pibarot P, Ramee SR, Rihal CS, Rodes-Cabau J, Sorajja P, Suri R, Swain JA, Turi ZG, Tuzcu EM, Weissman NJ, Zamorano JL, Serruys PW, Leon MB. Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis. Eur Heart J. 2018 04 14; 39(15):1224-1245. PMID: 28430909.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  34. Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Thanh Hai MT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. J Am Coll Cardiol. 2018 03 06; 71(9):1021-1034. PMID: 29495982.
    Citations: 32     Fields:    Translation:Humans
  35. Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Hai MTT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation. 2018 02 27; 137(9):961-972. PMID: 29483172.
    Citations: 59     Fields:    Translation:Humans
  36. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, Mickley H, Crea F, Van de Werf F, Bucciarelli-Ducci C, Katus HA, Pinto FJ, Antman EM, Hamm CW, De Caterina R, Januzzi JL, Apple FS, Alonso Garcia MA, Underwood SR, Canty JM, Lyon AR, Devereaux PJ, Zamorano JL, Lindahl B, Weintraub WS, Newby LK, Virmani R, Vranckx P, Cutlip D, Gibbons RJ, Smith SC, Atar D, Luepker RV, Robertson RM, Bonow RO, Steg PG, O'Gara PT, Fox KAA. [Fourth universal definition of myocardial infarction (2018)]. Kardiol Pol. 2018; 76(10):1383-1415. PMID: 30338834.
    Citations: 5     Fields:    Translation:Humans
  37. Stefanini GG, Cutlip D. Sorting out coronary stents, as time goes by. EuroIntervention. 2017 12 20; 13(11):1263-1265. PMID: 29260717.
    Citations:    Fields:    
  38. Yeh RW, Kereiakes DJ, Steg PG, Cutlip DE, Croce KJ, Massaro JM, Mauri L. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2017 Oct 31; 70(18):2213-2223. PMID: 29073947.
    Citations: 14     Fields:    Translation:Humans
  39. Kandzari DE, Mauri L, Koolen JJ, Massaro JM, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet. 2017 Oct 21; 390(10105):1843-1852. PMID: 28851504.
    Citations: 30     Fields:    Translation:Humans
  40. Doros G, Massaro JM, Kandzari DE, Waksman R, Koolen JJ, Cutlip DE, Mauri L. Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach. Am Heart J. 2017 Nov; 193:35-45. PMID: 29129253.
    Citations: 1     Fields:    Translation:Humans
  41. Lam DH, Glassmoyer LM, Strom JB, Davis RB, McCabe JM, Cutlip DE, Donnino MW, Cocchi MN, Pinto DS. Factors associated with performing urgent coronary angiography in out-of-hospital cardiac arrest patients. Catheter Cardiovasc Interv. 2018 04 01; 91(5):832-839. PMID: 28766924.
    Citations:    Fields:    Translation:Humans
  42. Seltzer JH, Heise T, Carson P, Canos D, Hiatt JC, Vranckx P, Christen T, Cutlip DE. Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortium. Am Heart J. 2017 Aug; 190:76-85. PMID: 28760216.
    Citations: 3     Fields:    Translation:Humans
  43. Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Steg PG, Massaro JM, Apruzzese PK, Mauri L. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. JACC Cardiovasc Interv. 2017 05 08; 10(9):942-954. PMID: 28473118.
    Citations: 4     Fields:    Translation:Humans
  44. Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Cohen DJ, Steg PG, Cannon CP, Apruzzese PK, D'Agostino RB, Massaro JM, Mauri L. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. JAMA Cardiol. 2017 05 01; 2(5):478-487. PMID: 28297015.
    Citations: 6     Fields:    Translation:Humans
  45. Ruiz CE, Hahn RT, Berrebi A, Borer JS, Cutlip DE, Fontana G, Gerosa G, Ibrahim R, Jelnin V, Jilaihawi H, Jolicoeur EM, Kliger C, Kronzon I, Leipsic J, Maisano F, Millan X, Nataf P, O'Gara PT, Pibarot P, Ramee SR, Rihal CS, Rodes-Cabau J, Sorajja P, Suri R, Swain JA, Turi ZG, Tuzcu EM, Weissman NJ, Zamorano JL, Serruys PW, Leon MB. Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis: An Expert Statement. J Am Coll Cardiol. 2017 Apr 25; 69(16):2067-2087. PMID: 28427582.
    Citations: 12     Fields:    Translation:Humans
  46. Drummond CA, Brewster PS, He W, Ren K, Xie Y, Tuttle KR, Haller ST, Jamerson K, Dworkin LD, Cutlip DE, Murphy TP, D'Agostino RB, Henrich WL, Tian J, Shapiro JI, Cooper CJ. Cigarette smoking and cardio-renal events in patients with atherosclerotic renal artery stenosis. PLoS One. 2017; 12(3):e0173562. PMID: 28306749.
    Citations: 4     Fields:    Translation:HumansAnimals
  47. Stefanescu Schmidt AC, Kereiakes DJ, Cutlip DE, Yeh RW, D'Agostino RB, Massaro JM, Hsieh WH, Mauri L. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). Circulation. 2017 May 02; 135(18):1720-1732. PMID: 28228427.
    Citations: 4     Fields:    Translation:Humans
  48. Lansky AJ, Messé SR, Brickman AM, Dwyer M, van der Worp HB, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, Browndyke J, Prendergast B, Ng VG, Cutlip DE, Kapadia S, Krucoff MW, Linke A, Moy CS, Schofer J, van Es GA, Virmani R, Popma J, Parides MK, Kodali S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, Holmes D, Kappetein AP, Mack M, Baumbach A. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. J Am Coll Cardiol. 2017 Feb 14; 69(6):679-691. PMID: 28183511.
    Citations: 11     Fields:    Translation:Humans
  49. Cutlip DE, Garratt KN, Novack V, Barakat M, Meraj P, Maillard L, Erglis A, Jauhar R, Popma JJ, Stoler R, Silber S. 9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System. JACC Cardiovasc Interv. 2017 01 23; 10(2):160-167. PMID: 28104210.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  50. Murphy TP, Cooper CJ, Pencina KM, D'Agostino R, Massaro J, Cutlip DE, Jamerson K, Matsumoto AH, Henrich W, Shapiro JI, Tuttle KR, Cohen DJ, Steffes M, Gao Q, Metzger DC, Abernethy WB, Textor SC, Briguglio J, Hirsch AT, Tobe S, Dworkin LD. Relationship of Albuminuria and Renal Artery Stent Outcomes: Results From the CORAL Randomized Clinical Trial (Cardiovascular Outcomes With Renal Artery Lesions). Hypertension. 2016 11; 68(5):1145-1152. PMID: 27647847.
    Citations: 11     Fields:    Translation:Humans
  51. Resor CD, Nathan A, Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Gabriel Steg P, Hsieh WH, Mauri L. Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study. Circulation. 2016 Oct 04; 134(14):989-998. PMID: 27576774.
    Citations: 4     Fields:    Translation:Humans
  52. Yang X, Tamez H, Lai C, Ho K, Cutlip D. Type 4a myocardial infarction: Incidence, risk factors, and long-term outcomes. Catheter Cardiovasc Interv. 2017 Apr; 89(5):849-856. PMID: 27535209.
    Citations: 9     Fields:    Translation:Humans
  53. Kalra A, Bhatt DL, Pinto DS, Kirtane AJ, Kapadia SR, Makkar RR, Rihal CS, Kleiman NS, Cutlip DE. Accreditation and funding for a 24-month advanced interventional cardiology fellowship program: A call-to-action for optimal training of the next generation of interventionalists. Catheter Cardiovasc Interv. 2016 Nov 15; 88(6):1010-1015. PMID: 27515241.
    Citations: 1     Fields:    Translation:Humans
  54. Généreux P, Kumsars I, Schneider JE, Lesiak M, Redfors B, Cornelis K, Selmon MR, Dens J, Hoye A, Metzger DC, Muyldermans L, Slagboom T, Francese DP, Ayele GM, Laak LL, Bartorelli AL, Cutlip DE, Kaplan AV, Leon MB. Dedicated Bifurcation Stent for the Treatment of Bifurcation Lesions Involving Large Side Branches: Outcomes From the Tryton Confirmatory Study. JACC Cardiovasc Interv. 2016 07 11; 9(13):1338-46. PMID: 27388820.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  55. Cutlip DE. Adapting DAPT to Improve Outcomes After Coronary Stenting. JACC Cardiovasc Interv. 2016 07 25; 9(14):1458-60. PMID: 27372194.
    Citations:    Fields:    
  56. Tuttle KR, Dworkin LD, Henrich W, Greco BA, Steffes M, Tobe S, Shapiro JI, Jamerson K, Lyass A, Pencina K, Massaro JM, D'Agostino RB, Cutlip DE, Murphy TP, Cooper CJ. Effects of Stenting for Atherosclerotic Renal Artery Stenosis on eGFR and Predictors of Clinical Events in the CORAL Trial. Clin J Am Soc Nephrol. 2016 07 07; 11(7):1180-8. PMID: 27225988.
    Citations: 7     Fields:    Translation:Humans
  57. Cutlip DE, Kramer DB. Value-Based Hypothesis Testing for Cardiac Device Clinical Trials: A Pathway for Accelerated Reimbursement Decisions. Circ Cardiovasc Interv. 2016 May; 9(5):e003627. PMID: 27094322.
    Citations:    Fields:    Translation:HumansPHPublic Health
  58. Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016 Apr 26; 315(16):1735-49. PMID: 27022822.
    Citations: 144     Fields:    Translation:Humans
  59. Smetana GW, Cutlip DE, Pinto DS. Should We Screen for Coronary Heart Disease in Asymptomatic Persons?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Ann Intern Med. 2016 04 05; 164(7):479-87. PMID: 27043981.
    Citations:    Fields:    Translation:HumansPHPublic Health
  60. Donnino MW, Andersen LW, Berg KM, Chase M, Sherwin R, Smithline H, Carney E, Ngo L, Patel PV, Liu X, Cutlip D, Zimetbaum P, Cocchi MN. Corticosteroid therapy in refractory shock following cardiac arrest: a randomized, double-blind, placebo-controlled, trial. Crit Care. 2016 Apr 03; 20:82. PMID: 27038920.
    Citations: 12     Fields:    Translation:Humans
  61. Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Steg PG, Wiviott SD, Mauri L. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. J Am Coll Cardiol. 2016 May 31; 67(21):2492-502. PMID: 27046159.
    Citations: 17     Fields:    Translation:HumansPHPublic Health
  62. Meredith IT, Tanguay JF, Kereiakes DJ, Cutlip DE, Yeh RW, Garratt KN, Lee DP, Steg PG, Weaver WD, Holmes DR, Brindis RG, Trebacz J, Massaro JM, Hsieh WH, Mauri L. Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. Circulation. 2016 May 03; 133(18):1772-82. PMID: 26994121.
    Citations: 13     Fields:    Translation:Humans
  63. Hermiller JB, Krucoff MW, Kereiakes DJ, Windecker S, Steg PG, Yeh RW, Cohen DJ, Cutlip DE, Massaro JM, Hsieh WH, Mauri L. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. JACC Cardiovasc Interv. 2016 Jan 25; 9(2):138-47. PMID: 26793956.
    Citations: 9     Fields:    Translation:Humans
  64. Chen SH, Ho KK, Gannon SA, Thyagarajan B, Chakrabarti AK, Potter BJ, Singla A, Piccirillo BJ, Meduri CU, Cutlip DE. Utility of a real-time appropriate use criteria decision support application for percutaneous coronary interventions in non-acute coronary syndrome. Catheter Cardiovasc Interv. 2016 Sep; 88(3):E74-9. PMID: 26699241.
    Citations:    Fields:    Translation:Humans
  65. Murphy TP, Cooper CJ, Matsumoto AH, Cutlip DE, Pencina KM, Jamerson K, Tuttle KR, Shapiro JI, D'Agostino R, Massaro J, Henrich W, Dworkin LD. Renal Artery Stent Outcomes: Effect of Baseline Blood Pressure, Stenosis Severity, and Translesion Pressure Gradient. J Am Coll Cardiol. 2015 Dec 08; 66(22):2487-94. PMID: 26653621.
    Citations: 6     Fields:    Translation:Humans
  66. Moore WS, Popma JJ, Roubin GS, Voeks JH, Cutlip DE, Jones M, Howard G, Brott TG. Carotid angiographic characteristics in the CREST trial were major contributors to periprocedural stroke and death differences between carotid artery stenting and carotid endarterectomy. J Vasc Surg. 2016 Apr; 63(4):851-7, 858.e1. PMID: 26610643.
    Citations: 9     Fields:    Translation:Humans
  67. Mauri L, Elmariah S, Yeh RW, Cutlip DE, Steg PG, Windecker S, Wiviott SD, Cohen DJ, Massaro JM, D'Agostino RB, Braunwald E, Kereiakes DJ. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J. 2016 Jan 21; 37(4):378-85. PMID: 26586780.
    Citations: 12     Fields:    Translation:Humans
  68. Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran R, Nissen SE, Smith EE, Targum SL. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Nucl Cardiol. 2015 Oct; 22(5):1041-144. PMID: 26204990.
    Citations: 11     Fields:    Translation:Humans
  69. Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. JACC Cardiovasc Interv. 2015 Oct; 8(12):1552-62. PMID: 26493248.
    Citations: 10     Fields:    Translation:Humans
  70. Généreux P, Kini A, Lesiak M, Kumsars I, Fontos G, Slagboom T, Ungi I, Metzger DC, Wykrzykowska JJ, Stella PR, Bartorelli AL, Fearon WF, Lefèvre T, Feldman RL, Tarantini G, Bettinger N, Minalu Ayele G, LaSalle L, Francese DP, Onuma Y, Grundeken MJ, Garcia-Garcia HM, Laak LL, Cutlip DE, Kaplan AV, Serruys PW, Leon MB. Outcomes of a dedicated stent in coronary bifurcations with large side branches: A subanalysis of the randomized TRYTON bifurcation study. Catheter Cardiovasc Interv. 2016 Jun; 87(7):1231-41. PMID: 26397982.
    Citations: 2     Fields:    Translation:Humans
  71. Krishnamurthy VN, Naeem M, Murphy TP, Cerezo J, Jordan PG, Goldberg SH, Ershow AG, Hirsch AT, Oldenburg N, Cutlip DE. The effect of gender on outcomes of aortoiliac artery interventions for claudication. Clin Imaging. 2016 Jan-Feb; 40(1):96-100. PMID: 26439658.
    Citations:    Fields:    Translation:Humans
  72. Kramer DB, Cutlip DE. Regulatory science: Trust and transparency in clinical trials of medical devices. Nat Rev Cardiol. 2015 Sep; 12(9):503-4. PMID: 26194550.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  73. Stone GW, Vahanian AS, Adams DH, Abraham WT, Borer JS, Bax JJ, Schofer J, Cutlip DE, Krucoff MW, Blackstone EH, Généreux P, Mack MJ, Siegel RJ, Grayburn PA, Enriquez-Sarano M, Lancellotti P, Filippatos G, Kappetein AP. Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles: A Consensus Document From the Mitral Valve Academic Research Consortium. J Am Coll Cardiol. 2015 Jul 21; 66(3):278-307. PMID: 26184622.
    Citations: 33     Fields:    Translation:Humans
  74. Stone GW, Vahanian AS, Adams DH, Abraham WT, Borer JS, Bax JJ, Schofer J, Cutlip DE, Krucoff MW, Blackstone EH, Généreux P, Mack MJ, Siegel RJ, Grayburn PA, Enriquez-Sarano M, Lancellotti P, Filippatos G, Kappetein AP. Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: A consensus document from the mitral valve academic research consortium. Eur Heart J. 2015 Aug 01; 36(29):1851-77. PMID: 26170467.
    Citations: 5     Fields:    Translation:Humans